Articles related to MAJOR ADVERSE CARDIAC EVENTS (MACE)

Higher circulating xylitol levels were associated with increased rates of major adverse cardiovascular events in two large population cohorts, although the observational findings do not establish that xylitol directly causes cardiovascular harm.

Targeted vitamin D supplementation successfully addressed widespread vitamin D insufficiency among post-myocardial infarction patients but did not significantly reduce major adverse cardiovascular events during more than four years of follow-up.

Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.

The FDA approved tirzepatide to reduce major cardiovascular event risk in high-risk adults with type 2 diabetes. SURPASS-CVOT established noninferiority to dulaglutide rather than cardiovascular superiority.

In a 10‑year cohort study, adults with irregular bedtimes and short sleep duration had nearly double the risk of heart attack or stroke, suggesting sleep timing may be a meaningful cardiovascular risk marker.

MACE was identified in 121 of 4267 patients (2.8%), including all-cause death (1.3%), cardiovascular death (0.7%), nonfatal MI (0.5%), and hospitalization for unstable angina (1.0%).